Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8305241 | 0.88 | KDM4E (0.52) | KDM4ECYP1A1CYP1A2CYP1B1ABCB1 | |
| SCHEMBL732875 | 0.84 | ALDH1A1 (0.43) | KDM4EALDH1A1MAPTCYP3A4USP2 | |
| SCHEMBL8308179 | 0.83 | HDAC6 (0.51) | KDM4EMAPTMEN1POLBKMT2A | |
| SCHEMBL30598448 | 0.81 | ALDH1A1 (0.43) | KDM4EALDH1A1MAPTCYP3A4USP2 | |
| SCHEMBL4574807 | 0.81 | ALDH1A1 (0.43) | KDM4EALDH1A1MAPTCYP3A4USP2 | |
| SCHEMBL8306763 | 0.80 | CYP1B1 (0.60) | KDM4EALDH1A1MAPTCYP3A4USP2 | |
| SCHEMBL8371953 | 0.79 | BCL2 (0.40) | KDM4EALDH1A1MAPTCYP3A4USP2 | |
| SCHEMBL8429609 | 0.79 | ALDH1A1 (0.53) | KDM4EALDH1A1MAPTCYP3A4USP2 | |
| SCHEMBL8431822 | 0.77 | ALDH1A1 (0.50) | KDM4EALDH1A1MAPTCYP3A4USP2 | |
| SCHEMBL8305425 | 0.76 | MAOB (0.53) | ALDH1A1MAPTCYP3A4MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0709383-B1 | Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-12-15 | — | — | EP | claimed |
| US-5629339-A | CHRONIC VENOUS INSUFFICIENCY | ADIR ET COMPAGNIE (FR) | 1997-05-13 | — | — | US | claimed |
| EP-0709383-A1 | Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1996-05-01 | — | — | EP | claimed |
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | LES LABORATOIRES SERVIER (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | LES LABORATOIRES SERVIER (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | LES LABORATOIRES SERVIER (FR) | 2008-07-24 | — | — | US | disclosed |
| EP-0709383-B1 | Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-12-15 | — | — | EP | disclosed |
| US-5629339-A | CHRONIC VENOUS INSUFFICIENCY | ADIR ET COMPAGNIE (FR) | 1997-05-13 | — | — | US | disclosed |
| EP-0709383-A1 | Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | ADAMTS13, ADAMTS1, SERPINC1 | KDM4E 2539/4885ALDH1A1 1798/4885MAPT 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.